Table 2.

Association between IL-22 and IL-22R expression and clinicopathologic characteristics.

		IL-22			IL-22R
Variables	N	Low	High	P value	Low	High	P value
Age, y
≤60	23 (76.7%)	18 (78.3%)	5 (21.7%)	.153	20 (87.0%)	3 (13.0%)	.565
>60	7 (23.3%)	3 (42.9%)	4 (57.1)		5 (71.4%)	2 (28.6%)
Gender
Male	25 (83.3%)	18 (72.0%)	7 (28.0%)	.662	21 (84.0%)	4 (16.0%)	>.99
Female	5 (16.7)	3 (60.0%)	2 (40.0%)		4 (80.0%)	1 (20.0%)
Tumor location
Supraglottic	22 (73.3%)	14 (63.6%)	8 (36.4%)	.374	18 (81.8%)	4 (18.2%)	>.99
Glottic	8 (26.7%)	7 (87.5%)	1 (12.5%)		7 (87.5%)	1 (12.5%)
T stage
T1–T2	10 (33.3%)	9 (90.0%)	1 (10.0%)	.204	10 (100%)	0 (0.0%)	.140
T3–T4	20 (66.7%)	12 (60.0%)	8 (40.0%)		15 (75.0%)	5 (25.0%)
Lymphatic metastasis
N0	17 (56.7%)	16 (94.1%)	1 (5.9%)	.002∗	17 (100%)	0 (0.0)	.009∗
N+	13 (43.3%)	5 (38.5%)	8 (61.5%)		8 (61.5%)	5 (38.5%)
Differentiation
High	11 (36.7%)	11 (100%)	0 (0.0%)	.061	10 (90.9%)	1 (9.1%)	.626
Moderate-poor	19 (63.3%)	13 (68.4%)	6 (31.6%)		15 (78.9%)	4 (21.1%)
Clinical stage
I + II	5 (16.7%)	5 (100%)	0 (0.0%)	.001∗	5 (100%)	0 (0.0%)	.037∗
III	17 (56.7%)	14 (82.4%)	3 (17.6%)		16 (94.1%)	1 (5.9%)
IV	8 (26.7%)	3 (37.5%)	5 (62.5%)		4 (50.0%)	4 (50.0%)

Fisher exact test. IL-22 = interlerukin-22, IL-22R = interleukin 22 receptor.

^∗P < .05.